| Treatment | Total costs | Total QALYs | ICER |
|---|---|---|---|
| 1: FEV1% utility | |||
| Macrolide (azithromycin) | £158,404 | 16.42 | - |
| Oral corticosteroid (prednisolone) | £289,619 | 14.57 | Dominated |
| NSAID (ibuprofen) | £291,035 | 14.32 | Dominated |
| “No treatment” | £302,045 | 14.52 | Dominated |
| Inhaled corticosteroid (fluticasone) | £411,046 | 13.11 | Dominated |
| 2: Azithromycin exacerbation data | |||
| Macrolide (azithromycin) | £132,480 | 14.56 | - |
| Oral corticosteroid (prednisolone) | £289,619 | 12.53 | Dominated |
| NSAID (ibuprofen) | £291,035 | 12.26 | Dominated |
| “No treatment” | £302,045 | 12.37 | Dominated |
| Inhaled corticosteroid (fluticasone) | £411,046 | 11.11 | Dominated |
| 3: Exacerbation cost | |||
| Macrolide (azithromycin) | £33,076 | 14.20 | - |
| NSAID (ibuprofen) | £55,785 | 12.26 | Dominated |
| “No treatment” | £57,220 | 12.37 | Dominated |
| Oral corticosteroid (prednisolone) | £67,160 | 12.53 | Dominated |
| Inhaled corticosteroid (fluticasone) | £81,318 | 11.11 | Dominated |
| 4: Number of baseline exacerbations reduced | |||
| Macrolide (azithromycin) | £93,787 | 15.10 | - |
| NSAID (ibuprofen) | £169,745 | 13.95 | Dominated |
| Oral corticosteroid (prednisolone) | £174,924 | 14.13 | Dominated |
| “No treatment” | £175,818 | 14.12 | Dominated |
| Inhaled corticosteroid (fluticasone) | £241,045 | 13.48 | Dominated |
| 5: Ibuprofen preparation | |||
| Macrolide (azithromycin) | £158,404 | 14.20 | - |
| Oral corticosteroid (prednisolone) | £289,619 | 12.53 | Dominated |
| NSAID (ibuprofen) | £293,107 | 12.26 | Dominated |
| “No treatment” | £302,045 | 12.37 | Dominated |
| Inhaled corticosteroid (fluticasone) | £411,046 | 11.11 | Dominated |
| 6: Prednisolone preparation | |||
| Macrolide (azithromycin) | £158,954 | 14.20 | - |
| NSAID (ibuprofen) | £291,035 | 12.26 | Dominated |
| “No treatment” | £302,045 | 12.37 | Dominated |
| Oral corticosteroid (prednisolone) | £340,317 | 12.53 | Dominated |
| Inhaled corticosteroid (fluticasone) | £411,046 | 11.11 | Dominated |
| 7: Probability of ibuprofen TRAEs increased | |||
| Macrolide (azithromycin) | £158,404 | 14.20 | - |
| NSAID (ibuprofen) | £287,655 | 12.08 | Dominated |
| Oral corticosteroid (prednisolone) | £289,619 | 12.53 | Dominated |
| “No treatment” | £302,045 | 12.37 | Dominated |
| Inhaled corticosteroid (fluticasone) | £411,046 | 11.11 | Dominated |
| 8: No TRAEs | |||
| Macrolide (azithromycin) | £138,541 | 14.48 | - |
| Oral corticosteriod (prednisolone) | £277,353 | 12.80 | Dominated |
| No treatment | £302,045 | 12.37 | Dominated |
| NSAID (ibuprofen) | £302,255 | 12.37 | Dominated |
| Inhaled corticosteriod (fluticasone) | £411,046 | 11.11 | Dominated |
| 9: Within-trial | |||
| Macrolide (azithromycin) | £9,583 | 1.31 | - |
| Oral corticosteroid (prednisolone) | £24,914 | 1.13 | Dominated |
| NSAID (ibuprofen) | £25,514 | 1.13 | Dominated |
| “No treatment” | £27,005 | 1.10 | Dominated |
| Inhaled corticosteroid (fluticasone) | £37,072 | 0.98 | Dominated |
| 10: Exacerbation (minor) | |||
| Macrolide (azithromycin) | £33,076 | 15.99 | - |
| NSAID (ibuprofen) | £55,785 | 15.62 | Dominated |
| “No treatment” | £57,220 | 15.86 | Dominated |
| Oral corticosteroid (prednisolone) | £67,160 | 15.70 | Dominated |
| Inhaled corticosteroid (fluticasone) | £81,318 | 15.82 | Dominated |
FEV, forced expiratory volume; ICER, incremental cost-effectiveness ratio; NSAID, nonsteroidal antiinflammatory drugs; QALYs; quality-adjusted life years; SA, sensitivity analysis; TRAE, treatment related adverse effect
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.